ATHX, Athersys, Inc.

** ATHX reported grant funding aggregating $3.6 million to further advance its MultiStem product programs and cell therapy platform.

Specifically, ATHX was awarded a SBIR Fast-Track grant of up to $1.9 million from the National Institute of Neurological Disorders and Stroke to develop MultiStem for the treatment of traumatic brain injury (TBI).

Athersys, Inc. (Nasdaq:ATHX) announced it ranked No. 488 on Deloitte's Technology Fast 500(TM) ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Athersys' revenue growth during the period covered by the ranking was 140%.

HIRU CORPORATION (Other OTC: HIRU.PK) subsidiary Jiangxi Shaungshi Pharmaceutical Co., Ltd launched the Jiangxi Shaungshi Biological Medicines Institute. Shuangshi AHP is currently researching several new veterinary drugs for development within the next two years. The company launched this new institute to strengthen and speed up the research and development processes.